CURRICULUM VITAE
`
`NAME
`NATIONALITY
`ADDRESS
`
`TELEPHONE & E-MAIL
`
`EDUCATION & ACADEMIC
`TRAINING
`
`CAREER SUMMARY
`(1983 – 1993)
`
`(1993 – 2000)
`
`(2000 – 2004)
`
`(2004 – Present)
`
`Joseph M.D. Fortunak
`United States citizen
`5 Countryside Court
`Silver Spring, MD 20905 USA
`+1 (202) 806 6880 (Office)
`+1 (301) 928 7568 (Mobile)
`jfortunak@comcast.net
`
`Purdue University
`BSc, Chemistry (1976)
`With highest distinction
`University of Wisconsin-Madison
`PhD, Organic Chemistry (1981)
`With highest distinction
`Cambridge University, United Kingdom
`Postdoctoral Fellow and Research Assistant
`Professor (1981-83)
`
`SmithKlineBeecham (GlaxoSmithKline)
`Pharmaceutical Corp. Associate Senior
`Research Investigator, Senior Research
`Investigator, Assistant Director
`DuPont Pharmaceutical Company
`Associate Director, Director,
`Senior Director, Executive Director
`Abbott Labs; Pharmaceutical Company
`Head of Global Chemical Development
`Howard University
`Professor of Chemistry and
`Pharmaceutical Sciences
`
`1
`
`IPR2018-00121
`
`Page 1 of 23
`
`I-MAK 1003
`
`

`

`PERSONAL STATEMENT OF PURPOSE
`
`I am a Professor at Howard University, a Research Tier-1, historically-black
`college/university (HBCU) in Washington, DC, USA.
`
`I have been a faculty member at Howard University with a joint appointment in the
`Departments of Chemistry and Pharmaceutical Sciences since 2004. My research group of
`PhD/PharmD/MSc and undergraduate students creates new science to decrease the cost
`and increase access to quality-assured medicines in less-developed countries. We have
`contributed new chemistry and technologies that have improved production and reduced the
`commercial prices of of several drugs for HIV/AIDS. We have discovered new, “green”
`chemistry to produce the malaria drugs amodiaquine, piperaquine, and lumefantrine. We
`have also worked on pediatric formulations for the Artemisinin Combination Therapies
`(ACTs) DHA:piperaquine and artesunate:amodiaquine. We also create new science to
`lower the dose and improve the safety of essential medicines to promote global access to
`medicines.
`
`In 2005 I helped found the Drug Access Technical Team (DAT) of the William J. Clinton
`Health Access Initiative (CHAI). I have had the privilege of contributing to successes in the
`following areas with CHAI to increase access to medicines for HIV/AIDS, malaria, and TB:
`
`1. The identification of suppliers meeting international standards of quality assurance for
`generic drug production
`2. Negotiating transparent, ceiling prices for Low- and Middle-Income Countries (LMICs)
`3. Providing technical assistance to generic suppliers to speed their time-to-market for
`WHO-Prequalified and US FDA-approved products.
`4. Assisting suppliers with achieving regulatory approval for new combinations of drugs
`(eg, ritonavir/atazanavir; efavirenz/tenofovir/lamivudine)
`5. Discovering and transferring novel technology to reduce the cost of Active
`Pharmaceutical Ingredients (APIs) for HIV/AIDS drugs, including: (a) efavirenz from
`$1100 to $105/kg; (b) tenofovir from $1100 to $140/kg; (c) ritonavir from $3000 to
`$450/kg; and (d) lopinavir from $1900 to $500/kg.
`
`2
`
`IPR2018-00121
`
`Page 2 of 23
`
`I-MAK 1003
`
`

`

`I presently work with organizations including the World Health Organization, UNITAID, and
`the Medicines Patent Pool on strategic market dynamics for essential medicines, novel
`chemistry and regulatory sciences for manufacturing, and regulation of quality-assured
`medicines for LMICs. I assisted UNIDO (United Nations Industrial Development
`Organization) and the UN ANDI (African Network for Drugs and Diagnostics Innovation)
`organizations in implementing the Pharmaceutical Manufacturing Plan for Africa,
`outlining a strategy that was approved by the Heads of State of the 54 nations of the
`Organization of African States in June 2012. That strategy has been used to create a
`National Strategic Plan for Local Pharmaceutical Manufacturing in Ethiopia (2015) in
`collaboration between the Government of Ethiopia, the WHO and UNIDO. A strategic
`national plan of action is also being developed for Nigeria (2017). I have been a consultant
`to the WHO, the Tony Blair Africa Governance Initiative (AGI), and the Governments of
`Ethiopia and Nigeria in developing these plans.
`
`I regularly teach (2-3 times a year) a curriculum of courses in drug development, GMP and
`quality-assurance at the University of Ibadan School of Pharmacy (Nigeria) and elsewhere
`in Africa (e.g., the St. Luke Foundation / Kilimanjaro School of Pharmacy in Moshi, TZ;
`SLF/KSP). Funding from the German GIZ (Gesellschaft fur Internaschenallen
`Zussamenarbeiten) and UNIDO was used to build and equip a drug development facility,
`classrooms, and a development laboratory at the SLF/KSP. Participants in this training
`include National Drug Regulators and African pharmaceutical professionals. Attendees learn
`how to detect counterfeit and substandard drugs, as well as the science and practice of drug
`development, GMP, quality-assurance and how to write Regulatory submissions. Our
`objectives are to assist National Drug Regulatory Agencies to achieve Strict Regulatory
`Authority status and to enable African companies to achieve WHO Prequalification status for
`their facilities and products. As of 2014 this effort has been expanded into a Master’s
`Degree program at both institutions.
`
`Our work was awarded the American Chemical Society’s Astellas Foundation award for
`“Chemistry Impact on Human Health” in 2009. I was one of four scientists representing the
`United States at the Chemical Sciences and Society Summit in Beijing, in September 2011.
`A White Paper from this Conference was provided to agencies of the US Government,
`including NSF, NIH, and the EPA. I also delivered invited presentations at the WHO ANDI
`
`3
`
`IPR2018-00121
`
`Page 3 of 23
`
`I-MAK 1003
`
`

`

`Stakeholders Meetings in Addis Ababa in October 2011 and January and November 2015.
`Our African partners have been designated as UN ANDI Centers of Excellence in Drug
`Manufacturing and Training, and Centers of Excellence in Regulatory Sciences. Our
`training course in reviewing generic drug submissions received a US FDA “Honor Award” for
`excellence and innovation in drug training and regulatory sciences. In 2013, I was a
`In
`recipient of a Team Award from the African Union for Corporate Social Responsibility.
`2015, I was appointed to the Scientific Advisory Board for the Royal Society of Chemistry
`(UK) “Green Chemistry” division. Most recently, in 2017 I was awarded an honorary
`membership of the National Association of Industrial Pharmacists by the Nigerian NAIP, and
`I am also a consultant for the Government of Ethiopia, the WHO and the Tony Blair Africa
`Governance Initiative on the National Strategy and Plan for Action for Local Pharmaceutical
`Manufacturing in Ethiopia.
`
`Prior to my faculty appointment, I worked as a scientist and manager in the Innovator
`Pharmaceutical Industry (from 1983-2004). During that time, I contributed to over 100 New
`Chemical Entities (NCEs) that moved from Discovery into Development. Thirteen of these
`new products were approved for commercial marketing, including important drugs for
`HIV/AIDS, cardiovascular and cancer therapeutics. In my most recent (2001-2004) industrial
`position I was the Head of Global Chemical Development for a major healthcare company,
`Abbott Labs, administering annual budgets of up to $150MM and managing over 400
`scientists and technical staff. I am intimately familiar with the science and technology of
`Active Pharmaceutical Ingredient (API) and finished pharmaceutical product (FPP) drug
`production. I also have extensive, hands-on knowledge of drug patents, quality assurance,
`drug regulation, salt selection and physicochemical properties, clinical and marketing (IND
`and NDA) submissions, and Current Good Manufacturing Practice (cGMP). I was a
`company representative to the Pharmaceutical Research and Manufacturers Association
`(PhRMA) Technical Group and contributed to industry collaborations with the US FDA in
`drafting the ICH Q7A Guidance governing cGMP for the production of APIs.
`
`RECENT AWARDS AND APPOINTMENTS
`
`4
`
`IPR2018-00121
`
`Page 4 of 23
`
`I-MAK 1003
`
`

`

`1. Consultant to the WHO and the Government of Ethiopia in formulating and implementing
`the National Strategic Plan for Local Pharmaceutical Manufacturing (2016-2017).
`2. Consultant to UNAIDS on the Strategic Market Dynamics of implementing Pre-exposure
`Prophylaxis (PrEP) as part of the long-term plan for eliminating HIV/AIDS (2016-2017).
`3. Royal Society of Chemistry’s “Green Chemistry” Scientific Advisory Board (May, 2015).
`4. Howard University Faculty Senate Award for contributions to Africa and the African
`Diaspora (May, 2014).
`5. Appointment as an Associate Lecturer, University of Ibadan, (May, 2014).
`6. African Medicines Regulatory Harmonization (AMRH) designated RCORE Center of
`Excellence in Regulatory training; St. Luke Foundation / Kilimanjaro School of Pharmacy
`Industrial Pharmacy Advanced Training (IPAT); Moshi, TZ (April, 2014).
`7. WHUR radio interview with our research group on green chemistry and increasing global
`access to medicines, broadcast on February 13, 2014 available at:
`http://wamu.org/programs/metro_connection/13/02/14/this_week_on_metro_connection_
`chemistry_transcript
`8. United Nations Industrial Development Organization (UNIDO) Consultancy on training
`needs of the South African Pharmaceutical Industry for achieving Strict Regulatory
`Authority Status (December, 2013).
`9. African Union Commission Award for Corporate Social Responsibility (Team),
`(September 2013).
`10. US FDA Honor Award (Team); Kilimanjaro School of Pharmacy IPAT for Excellence and
`Innovation in regulatory sciences, (September, 2013).
`11. “Howard Prof. relies on green chemistry to improve drugs,” Interview with National Public
`Radio reporter Jonathan Wilson broadcast on February 15, 2013. Available on the
`Internet at WAMU Radio 88.5 “Metro Connection” at:
`http://wamu.org/programs/metro_connection/13/02/15/howard_prof_relies_on_green_ch
`emistry_to_improve_drugs
`12. Appointed member of the Strategic Advisory Group for funding priorities, UNITAID
`(2012-2013).
`13. Host of the American Chemical Society Webinars on “Green Chemistry” (2012-present;
`4-times yearly event).
`14. Posted on the American Chemical Society’s Nexus Blog: “Dr. Joseph Fortunak: Green
`Chemistry and Equal Access to Medicines,” by Christiana Briddell, December 7, 2012.
`Accessible at: https://communities.acs.org/community/science/sustainability/green-
`chemistry-nexus-blog/blog/2012/12/07/dr-joseph-fortunak-green-chemistry-and-equal-
`access-to-medicines
`15. United Nations ANDI (African Initiative for New Drugs and Diagnostics) designated
`Center of Excellence in drug manufacturing and training; St. Luke Foundation /
`Kilimanjaro School of Pharmacy IPAT (2012).
`16. Invited Presenter - American Chemical Society Webinar: “Chemistry, Human Rights, and
`Health,” April 18, 2012. Accessible at:
`
`5
`
`IPR2018-00121
`
`Page 5 of 23
`
`I-MAK 1003
`
`

`

`http://www.acs.org/content/acs/en/global/international/science-and-human-
`rights/webinars.html.html
`17. Invited Presenter - American Chemical Society Webinar: “Green Chemistry and Global
`Access to Medicines,” presented June 14, 2012
`http://article.wn.com/view/2014/07/01/Taxing_the_Sick/
`18. One of four external scientists selected to represent the United States at the “Chemical
`Sciences, Society, and Sustainability” (CS3) summit in Beijing, China (September,
`2011). The White Paper resulting from this meeting is available at:
`http://www.acs.org/content/acs/en/global/international/regional/eventsglobal/cs3.html .
`19. “Researchers manipulate drug’s chemistry in bid to lower treatment cost,” Wall Street
`Journal, May 13, 2011. This article described our new chemistry at Howard University
`to lower the costs of the HIV/AIDS drug tenofovir disoproxil fumarate. Available at:
`http://online.wsj.com/news/articles/SB1000142405274870373080457631948099082542
`2
`20. American Chemical Society “Astellas Foundation” Prize for Chemistry Impact on
`Human Health; included $40,000 unrestricted R&D cash award (ACS National Meeting,
`August 16, 2009).
`21. Appointed external Co-Director of the St. Luke Foundation / Kilimanjaro School of
`Pharmacy “Industrial Pharmacy Advanced Training” (IPAT) Program: August, 2008.
`22. Editorial Board, Tropical Journal of Pharmaceutical Research (2008-present)
`23. Appointed member of Nigerian National Institute of Pharmaceutical R&D (NIPRD);
`Expert Scientific Advisory Committee (ESAC; July, 2008).
`24. Appointed member of World Health Organization’s Stop TB Secretariat “Global Drug
`Facility” Business Advisory Committee (2006-2012).
`25. Editorial Board, Current Opinion in Drug Discovery and Development (2004-2009)
`Other Awards
` State of Illinois Governor’s Pollution Prevention Team Award (2004)
` Corporate Award from Abbott Labs for manufacturing improvements the reduced the
`rate of volatile organic emissions (VOEs) over the island of Puerto Rico by 60% (2004)
` Howard University Fund for Academic Excellence (2006)
` National Science Foundation (USA), Discovery Corps Senior Fellow (2006-2008)
` Collaboration with the African Union – a Business Plan for the Pharmaceutical
`Manufacturing Plan for Africa (2011-2012); approved by the Heads of State of the 54
`countries comprising the African Union
` Consultant; Medicines Patent Pool; (2012-present)
` Partners for Supply Chain Management (SCMS) / USAID collaborative consulting; waste
`reduction and expired drug recycling in Africa, Latin America, and the Caribbean and
`member of the SCMS Quality Assurance Advisory Panel (2013-2016).
`
`6
`
`IPR2018-00121
`
`Page 6 of 23
`
`I-MAK 1003
`
`

`

`SERVICE AND CONSULTING
`
`Bill, Hillary, and Chelsea Clinton Foundation Healthcare Access Initiative (August 2005-
`2016)
`
`See above for a description of this work.
`
`St. Luke Foundation / Kilimanjaro School of Pharmacy IPAT (Industrial Pharmacy
`Training Unit); and University of Ibadan, School of Pharmacy (2007 - present)
`External Director of the IPAT, designated as a Center of Excellence in Africa for drug
`manufacturing and training by the WHO ANDI (African Initiative for New Drugs and Diagnostics;
`2012). The IPAT provides professional training for African Drug Regulators and pharmaceutical
`professionals to eliminate counterfeit and substandard medicines from the market and to enable
`African pharmaceutical companies to manufacture essential medicines meeting all international
`standards of Quality-Assurance.
`
`Medicines sans Frontieres (MSF; Doctors Without Borders, and Medicines Patent Pool) –
`(2006; 2010; 2013-2014)
`Consultancy evaluating Brazilian pharmaceutical companies and their potential to produce
`HIV/AIDS drugs and APIs with quality-assurance and cost-competitive with Indian/Chinese
`generic products. Assistance evaluating technology transfer packages for the “Patent Pool”
`enabling the generic production of critical medicines for the treatment of HIV/AIDS, malaria, and
`tuberculosis.
`
`Brazilian Ministry of Health (September, 2010, January, 2014)
`One-week courses training the Brazilian pharmaceutical industry in the production of the
`HIV/AIDS drug efavirenz. One week of training in drug development and green chemistry for
`drug manufacturing. Collaborative work on continuous flow processing to produce intermediates
`for HIV/AIDS medications.
`
`WHO “Stop TB” Campaign – Global Drug Facility, Business Advisory Council (BAC; 2006
`– 2012)
`Member of the Business Advisory Council, Global Drug Facility (GDF) of the WHO Stop TB
`Secretariat. The mission of the GDF is to provide effective medicines for the treatment of
`tuberculosis with assured quality.
`
`7
`
`IPR2018-00121
`
`Page 7 of 23
`
`I-MAK 1003
`
`

`

`UNITAID Advisory Group on Funding Priorities (2012-2013)
`UNITAID is an organization with $400-500 million/year in funding whose strategic objective is to
`introduce new commodities into markets for developing nations that will 1) significantly improve
`global health; and 2) be sustainable for lasting impact. Examples of UNITAID initiatives include
`the introduction of generic pediatric medicines for HIV in Sub-Saharan Africa. My work with
`UNITAID includes co-authorship of the 2014 “Global HIV Medicines Landscape” and assisting
`UNITAID and the WHO in assuring the supply of quality-assured medications for clinical trials of
`HIV/AIDS and HCV treatments in children, women, and for patients with HIV-TB co-infection.
`
`National Academy of Sciences and American Chemical Society (NAS, ACS)
` NAS council on “Grand Challenges for Sustainability in the Chemical Industry” (2005)
` NAS “Green Chemistry Education Committee” (2005 – 2007)
` ACS “Strategic Redesigning the Petroleum Research Fund” (2007 - 2008)
` NAS “Committee on Chemical Substitution in Industry” (2008)
` Organizer, ACS Symposium on Process Chemistry in the Pharmaceutical and
`Agricultural Industries (2008)
` Session Chair, ACS Symposium on Green Chemistry and Chemical Manufacturing; ACS
`239th National Meeting, (August, 2009)
` Reviewer on Panel for funding of the ACS Teva Grants Panel (2009)
` Reviewer on Panel for REU Grants (2011, 2013)
` Reviewer on Panel for ACS GREET Awards (2012)
` Member of the ACS “Motivational Speakers Bureau” (2012)
` Host of the American Chemical Society’s “Green Chemistry” Webinar Series (2012-
`2014)
` Presenter (twice) of Chemistry for the improvement of global health and green chemistry
`for developing nations for the ACS’ Webinar series (2012, 2013)
` Organizer and Session Chair, “Industrial Applications of Green Chemistry,” Green
`Chemistry International meeting, Rockville, MD; June 18-20, 2014.
` Reviewer for the “Presidential Green Chemistry Awards” (American Chemical Society),
`2015, 2016.
`
`8
`
`IPR2018-00121
`
`Page 8 of 23
`
`I-MAK 1003
`
`

`

`Adjunct Professor
` University of Alabama, Green Chemistry Manufacturing Institute (2006 – 2014)
` St. Luke Foundation / Kilimanjaro School of Pharmacy, Industrial Pharmacy Advanced
`Training (2008 - present)
` University of Ibadan, School of Pharmacy (2014 - present)
`
`
`
`
`
`Advisory Boards of Commercial Entities or NGOs
`LaGray Foundation for Drug Discovery and Development for Neglected Populations
`(Nsawam, Ghana)
`Initiative for Medicines Access and Knowledge (New York, NY and India; 2006 -
`present)
` Arvir Chemical manufacturing company (2007-2010), Republic of South Africa
` UNITAID Advisory Group on Funding Priorities (2011-2012)
` Scientific Advisory Committee, AviMed Pharma. AviMed is a biotechnology startup
`company involved in drug discovery for Schizophrenia and Alzheimer’s disease (2012)
` Scientific Advisory Board for the Public-Private Partnership “PlantSource” with the
`objective of bringing reliable medicines for malaria to the market at a cost of not more
`than $0.10 per treatment (2012)
` Scientific Advisory Board for “Cosmic Therapeutics”, India (2015)
`
`Nigeria, Zimbabwe and LIberia (2005 - Present)
` Taught the first training course on GMP production of medicines in West Africa; Abuja,
`Nigeria, July 11 – 16, 2005.
` Collaborating with the National Institute of Pharmceutical R&D in Nigeria (NIPRD), NIH
`and USAID to construct a facility to prepare generic antimalarial drugs (2006 – 2008;
`2011-2012)
` Co-PI; grant from the USAID-UNCF Program to help re-build the University infrastructure
`for the AME University of Liberia (2007)
` Organized, arranged funding from the National Science Foundation (USA) and co-
`hosted an International Workshop on Green Chemistry and the Production of Essential
`Medicines, March 17-20, 2008
` Member, External Scientific Advisory Committee (ESAC) for NIPRD, (2008-2010)
`
`9
`
`IPR2018-00121
`
`Page 9 of 23
`
`I-MAK 1003
`
`

`

` Member of the Organizing Committee, Conference on Green Chemistry and
`Conferences on Appropriate Technologies in Africa; Zimbabwe (2006), Rwanda (2008),
`South Africa (2007), and Ghana (2010)
` Co-PI on a MacArthur Foundation Award to the University of Ibadan, Nigeria for drug
`discovery, development and quality-assurance (2012-2015)
`
`Editorial Boards, Scientific Journals
`“Current Opinion in Drug Discovery and Development” 2006 – 2011
`“Journal of Tropical Pharmaceutical Research” 2008 – present
`“Green Chemistry Journal” – Royal Society of Chemistry 2015-present
`
`
`
`
`
`RESEARCH ACTIVITIES
` New synthetic chemistry and methodology for the manufacture of essential medicines for
`the treatment of HIV/AIDS, malaria and tuberculosis
` New technologies for Green Chemistry, safety and waste reduction
` Teaching drug development and industrial pharmacy in Low- and Middle-Income
`Countries to enable local production according to international standards of Current
`Good Manufacturing Practice (cGMP)
`
`PREVIOUS WORK EXPERIENCE
`
`Head of Global Process R&D Division; Abbott Labs (12/2000 – 6/2004)
`Managed 225 - 450 employees, ~50% PhDs. Responsible for API and physicochemical pre-
`formulation activities for all new drug candidates; route discovery, polymorph control, clinical
`supplies, analytical & process development and validation for Abbott and external customers.
`Manufactured several small-volume, commercial products. Group consisted of:
` Analytical – Developed and validated test methods for intermediates, in-process
`controls, APIs and cleaning; specifications and Process Analytical Technologies (PATs)
` Pilot Plants - Operated three pilot plants and a potent drug facility for R&D, commercial,
`and 3rd party manufacturing under cGMP.
` Chemistry - Route discovery, development and clinical API supplies from first-in-man
`through process validation and commercial launch
`
`10
`
`IPR2018-00121
`
`Page 10 of 23
`
`I-MAK 1003
`
`

`

` Engineering - Engineering development and technology transfer with special expertise in
`solid state, thermochemistry, kinetics, and hazards evaluation.
`
`MAJOR ACCOMPLISHMENTS WITH ABBOTT LABS
` Created a Process Engineering Department with expertise in separations sciences,
`solids engineering and process modeling.
` Solid State Chemistry. Hired world-class scientists to decrease by 80% the API needed
`to develop a commercial formulation.
` Validated processes for four New Drug Applications including the XIENCE™ V drug-
`device combination and the nucleotide anti-retroviral drug emtricitabine/Coviracil™
` Founded a Green Chemistry program that reduced waste by 45% in chemical pilot
`plants and reduced Volatile Organic Emissions over Puerto Rico by 65%
`
`
`
`
`
`MAJOR ACCOMPLISHMENTS WITH DuPONT PHARMA (8/1993 – 12/2000)
`Led the CMC (Chemistry, Manufacturing, Controls) development team for Losoxantrone
`(breast cancer) including Regulatory, marketing application and pre-approval
`inspections.
`Led the API development team for the HIV drug Efavirenz, an inhibitor of HIV-1 reverse-
`transcriptase
`
`MAJOR ACCOMPLISHMENTS WITH SMITHKLINE BEECHAM CO. (7/1983 – 8/1993)
`Invented commercial API processes for the FDA-approved drugs Halofantrine,
`
`Ropinerole, Topotecan, and Eprosartan.
`
`SUMMARY OF PREVIOUS EXPERIENCE
`I have been responsible for creating and implementing the vision of chemical and
`pharmaceutical drug development in Pharmaceutical R&D. I have invented new chemical
`reactions and processes, and have an extensive record of publications, patents and
`presentations. I am experienced in dealing with commercial and contract manufacturers, the US
`FDA and other Regulatory agencies. I worked on the industry initiatives PQRI, BACPAC I & II
`and the PhRMA Technical Group. Production processes for commercially-approved new drugs
`that I significantly contributed to include:
`
`11
`
`IPR2018-00121
`
`Page 11 of 23
`
`I-MAK 1003
`
`

`

`Drug
`Halofantrine
`Ropinerole
`
`Proprietary Name (™)
`Halfan
`Requip
`
`Topotecan
`
`Hycamptin
`
`Eprosar
`
`Indication
`Malaria
`Parkinson's Disease,
`Restless-leg syndrome
`Ovarian, Breast and Small-
`Cell Lung cancer
`Hypertension; Heart Failure
`Breast cancer
`HIV/AIDS
`Breast, Ovarian cancer and
`Karposi’s sarcoma
`HIV/AIDS
`HIV/AIDS
`Drug/Device combination for
`restenosis after coronary angioplasty
`HIV/AIDS
`Tenofovir Disoproxil Viread
`Fumarate (TDF)
`(With generic companies operating under license from the innovator
`company, Gilead Sciences)
`Trilipix™
`Febuxostat™
`
`Eprosartan
`Losoxantrone
`Efavirenz
`Paclitaxcel
`
`Sustiva
`(NaPro
`BioTherapeutics)
`Coviracil
`Emtricitabine
`Kaletra (heat stable) Lopinavir/Ritonavir
`XIENCE™ V
`Everolimus
`
`Fenofibric Acid
`Uloric
`
`Cholesterol management
`Gout
`
`OTHER EXTERNAL ACCOMPLISHMENTS
` Scientific Advisory Board - NaPro Biotherapeutics, Boulder, CO, 1993-1999 Commercial
`semi-synthesis of paclitaxcel from renewable biomass.
` Speaker - US FDA internal sessions to train inspectors on Marketing Applications and Pre-
`Approval Inspections (1997)
` Chair - Regulatory and Compliance Section for the Midwest Pharmaceutical Process
`Chemistry Consortium (2001 – 2004)
`
`PUBLICATIONS
`1. Trost, B.M., Verhoeven, T., and Fortunak, J.M., “Isomerization of Allylic Acetates Catalyzed
`by Palladium. New Method for Stereocontrol” Tetrahedron Letters, 2301, 1979.
`2. 2. Trost, B.M. and Fortunak, J.M. "A New Diene Synthesis via Organopalladium Chemistry”
`J. Am. Chem. Soc., 102, 2841, 1980.
`
`12
`
`IPR2018-00121
`
`Page 12 of 23
`
`I-MAK 1003
`
`

`

`3. Trost, B.M. and Fortunak, J.M., "Palladium-Catalyzed Fragmentation Reaction as an
`Approach to Vitamin A Ester" Tetrahedron Letters, 22, 3459, 1981.
`4. Trost, B.M. and Fortunak, J.M. "Cyclizations Initiated by a Pd2+-Ag+ Mixed-Metal System"
`Organometallics, 1, 7, 1982.
`5. Fleming, I., Murahashi, S.-I., Naota, T., Tanigawa, Y. and Fortunak, J., “Palladium-
`Phosphine Complex Catalyzed Reaction of Organolithium Compounds and Alkenyl Halides:
`(Z)-β-[2-(N,N-dimethylamino)phenyl]styrene” Organic Syntheses, Vol. 62, 1984, p. 39.
`6. Fleming, I., Fortunak, J.M., et al., “An Approach to the Synthesis of Gelsemine” New Trends
`in Natural Products Chemistry, Atta-ur-Rahman, LeQuesne, Eds.; Elsevier: Amsterdam,
`1986, p. 83.
`7. McMurry, J.E., Musser, J.H., Fleming, I., Fortunak, J. and Nubling, C., “Preparation of β-nitro
`acrylic ester” Organic Syntheses, Coll. Vol. 6, 1988, p. 799.
`8. 8. Fleming, I., Fortunak, J.M. et al., "An Approach to the Synthesis of Gelsemine"
`Tetrahedron, 44, 3931-3944, 1988.
`9. Fortunak, J.M., Mellinger, M. and Wood, J. "A Convenient Preparation of Mappicine Ketones
`from Camptothecins: Chemistry of the Camptothecin E-Ring" Tetrahedron Letters, 35, 5763,
`1994.
`10. Fortunak J.M., Walsgrove, T.C., Giles, R.G., et al. "Some Synthetic Approaches to
`Ropinerole (SK&F 101468-A): A Potent Dopamine Receptor Antagonist" J. Het. Chem. 32,
`875, 1995.
`11. Wood, J.L., Fortunak, J.M., Mastrocola, A.R., Mellinger, M., and Burk, P.L. “An Efficient
`Conversion of Camptothecin to 10-Hydroxycamptothecin.” J. Org. Chem., 60, 5739, 1995.
`12. Pierce, M.E., Islam, Q. and Fortunak, J.M. "A Practical Photochemical Synthesis of 6-Aza-
`1,10-Phenanthroic Anhydride" Synth. Commun. 26, 3645, 1996.
`13. Fortunak, J.M.D., Mastrocola, A.R., Mellinger, M., Sisti, N.J., Wood, J.L., and Zhuang, Z.-P.
`"Novel Syntheses of Camptothecin Alkaloids, Part 1. Intramolecular [4+2] Cycloadditions of
`N-Arylimidates and 4H-3,1-Benzoxazin-4-ones as 2-Aza-1,3-Dienes" Tetrahedron Letters,
`37, 5679, 1996.
`14. Fortunak, J.M.D., Kitteringham, J., Mastrocola, A.R., Mellinger, M., Sisti, N.J., Wood, J.L.
`and Zhuang, Z.-P. "Novel Syntheses of Camptothecin Alkaloids, Part 2. Concise Synthesis
`of (S)-Camptothecins" Tetrahedron Letters, 37, 5683, 1996.
`15. Shilcrat, S.C., Mokhallalati, M.K., Fortunak, J.M.D. and Pridgen, L.N. "A New,
`Regioselective Synthesis of 1,2,5-Trisubstituted 1H-Imidazoles and Its Application to the
`Development of Eprosartan" J. Org. Chem., 62, 8449, 1997.
`16. Wang, Z., La, B., and Fortunak, J.M. "Enantioselective Synthesis of α-Hydroxy Carboxylic
`Acids: Direct Conversion of α-Oxocarboxylic Acids to Enantiomerically Enriched α-Hydroxy
`Carboxylic Acids via Neighboring Group Control" Tetrahedron Letters, 39, 5501, 1998.
`17. Williams, R.C., Riley, C.M., Sigvardson, K.W., Fortunak, J., Ma, P., Nicolas, E.C., Unger,
`S.E., Krahn, D.F. and Brenner, S.L. "Pharmaceutical Development and Specification of
`Stereoisomers" J. Pharm. Biomed. Anal., 17, 917, 1998.
`18. Pierce, M.E., Parsons, R.L., Radesca, L.A., Fortunak, J.M.D., et al. "Practical Asymmetric
`Synthesis of Efavirenz (DMP-266) an HIV-1 Reverse Transcriptase Inhibitor" J. Org. Chem.,
`63, 8536, 1998.
`
`13
`
`IPR2018-00121
`
`Page 13 of 23
`
`I-MAK 1003
`
`

`

`19. Wang, Z., Zhao, C., Pierce, M.E. and Fortunak, J.M. “Enantioselective Synthesis of β-
`Hydroxy Carboxylic Acids...” Tetrahedron Asymmetry, 10, 225, 1999.
`20. Wang, Z., Yin, J.G., Campagna, S., Pesti, J.A. and Fortunak, J.M. “An Alternative Approach
`for the Conversion of Aldehydes to Terminal Alkynes” J. Org. Chem., 64, 6918, 1999.
`21. Kauffman, G.S., Harris, G.D., Dorow, R.L., Stone, B.R.P., Parsons, R.L., Pesti, J.A.,
`Magnus, N.A., Fortunak, J.M., Confalone, P.N. and Nugent, W.A. “An Efficient Chiral
`Moderator Prepared from Inexpensive (+)-3-Carene: Synthesis of ...DPC 963” Organic
`Letters, 2, 3119, 2000.
`22. Wang, Z., Campagna, S., Xu, G., Pierce, M.E., Fortunak, J.M. and Confalone, P.N. “A New
`and Practical Synthesis of Vinyl Dichlorides via a non-Wittig-Type Approach” Tetrahedron
`Letters, 41, 4007, 2000.
`23. Wang, Z., Fortunak, J.M. et al. "A Practical Preparation of Terminal Alkynes From
`Aldehydes" J. Org. Chem., 65, 1889, 2000.
`24. Fortunak, J.M., Pesti, J.A., Earl, R.A. et al., “Efficient Pyridinylmethyl Functionalization:
`Synthesis of 10,10-Bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone (DMP 543), an
`Acetylcholine Release Enhancing Agent” J. Org. Chem., 65, 7718-7722, 2000.
`25. Parsons, R.L., Fortunak, J.M., Collum, D.B., et al. "NMR Spectroscopic Investigations of
`Mixed Aggregates Underlying Highly Enantioselective 1,2-Additions of Lithium
`Cyclopropylacetylide to Quinazolinones" J. Am. Chem. Soc. 123, 9135, 2001.
`26. Sigvardson, K.W., Adams, S.P., Barnes, T.B., Blom, K.F., Fortunak, J.M., Haas, M.J., Reilly,
`K.L., Repta, A.J. and Nemeth, G.A. “The Isolation and Identification of a Toxic Impurity in
`XP315 Drug Substance” J. Pharm. Biomed. Anal., 27(1-2), 327, 2002.
`27. Fortunak, J.M., Storace, L., Confalone, P.N. et al., “An Efficient Large-Scale Process for the
`Human Leukocyte Elastase Inhibitor, DMP 777” J. Org. Proc. Res. Dev., 6(1), 54, 2002.
`28. Choudhury, A., Moore, J.R., Pierce, M.E., Fortunak, J.M., Valvis, I.I. and Confalone, P.N. “In
`situ Recycling of Chiral Ligand and Surplus Nucleophile for a non-Catalytic Reaction:
`Amplification of Process Throughput in the Asymmetric Addition Step of Efavirenz (DMP
`266)” J.Org. Proc. Res. Dev., 7(3), 324, 2003.
`29. Pesti, J.A., Yin, J., Fortunak, J., et al., “Efficient Preparation of a Key Intermediate in the
`Synthesis of Roxifiban by Enzymatic Dynamic Kinetic Resolution” J. Org. Proc. Res. Dev.,
`8(1), 22, 2004.
`30. Briggs, T.F., Collum, D.B., Fortunak, J.M., et al., “Structural and Rate Studies of the 1,2-
`Additions of Lithium Phenylacetylide to Lithiated Quinazolinones: Influence of Mixed
`Aggregates on the Reaction Mechanism.” J, Am, Chem. Soc., 126, 5427, 2004.
`31. Yue, T.-Y., McLeod, D.D., Albertson,, K.R., Beck, S.R., Deerberg, J., Fortunak, J.M.,
`Nugent, W.A., Radesca, L.A., Tang, L., and Xiang, C.D. “Stereoselective Process for a
`CCR3 Antagonist” J. Org. Proc. Res. Dev., 226, 2006
`32. Yue, T.-Y., McLeod, D.D., Albertson,, K.R., Beck, S.R., Deerberg, J., Fortunak, J.M.,
`Nugent, W.A., Radesca, L.A., Tang, L., and Xiang, C., “Synthesis of a CCR3 Antagonist”
`Synfacts, 2006(9):0863, 2006.
`33. Fortunak, J.M.D.;* King, C.L.; Silverton, T.; Ohwoavworhua, F.; Swatloski, R.; and Kunle,
`O.O. “Valuable Products Derived from Nigerian Grasses.” In: Proceedings from the 2nd
`International Conference on Appropriate Technology. National University of Science and
`Technology (NUST), Zimbabwe, July 12 – 15, 2006.
`
`14
`
`IPR2018-00121
`
`Page 14 of 23
`
`I-MAK 1003
`
`

`

`34. Fortunak J, Confalone PN, Grosso JA “Strength and Honor through the Pharmaceutical
`Industry’s Embrace of Green Chemistry?” Current Opinion in Drug Discovery and
`Development, 10(6), 651-653 2007.
`35. Pinheiro, E.D-S.; Antunes, O.A.C.; Fortunak, J.M.D. “A Survey of the syntheses of active
`pharmaceutical ingredients for anti-retroviral drug combinations critical for emerging
`nations.” Journal of Antiviral Research, 79, 143 – 165, 2008.
`36. Fortunak, J.M.D. “Green Chemistry and Developing New Industrial Production in Africa: a
`Critical Balance.” Tropical Journal of Pharmaceutical Research, 7(1), 865 – 866, 2008.
`37. O.O. Kunle, J.M. Fortunak, R.D. Rogers, “Workshop in green chemistry and production of
`essential medicines,” Green Chemistry, 10, 823-824, 2008.
`38. Fortunak JM, “Process development in developing countries” Current Opinion in Drug
`Discovery and Development, 2008, 11(6); 751-3.
`39. Emeje M, Nwabunike P, Isimi C, Fortunak J, Mitchell JW, Byrn, S, Kunle O, Ofoefule S,
`“Isolation characterization and formulati